Healthcare
Verici Dx plc(VRCDF)
Live Price
Offline$0.003
+0.00% today
1Y Change
-90.00%
Window
Jun 23, 2025 โ Jun 18, 2026
- Market Cap
- $10.00M
- Revenue Growth
- +229.6%
- EPS Growth
- +51.3%
- Dividend Yield
- 0.0%
Coverage: 249 bars ยท Jun 23, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Verici Dx plc (VRCDF) is a Healthcare stock with a market cap of $10.00M and listed on OTC. The stock last traded around $0.00 and down 90.0% across the available one-year price window (Jun 23, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of +229.6%, EPS growth of +51.3%, a dividend yield of 0.0%. What stands out right now is revenue +229.6%, EPS +51.3%, free cash flow +15.9% with operating margin -472.6% and ROIC -243.2%. Valuation sits in the middle of the pack at price/sales 6.7. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines VRCDF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+229.6% vs +7.6% peer median
Operating Margin
Below sector median
-472.6% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Apr 15, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +229.6% and EPS at +51.3%, with operating margin around -472.6%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged 0.0% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Apr 15, 2026 | โ | +0.0% | +0.0% | +0.0% |
2025 Jul 18, 2025 | โ | +0.0% | +0.0% | -24.0% |
2025 May 28, 2025 | โ | +0.0% | +0.0% | -66.7% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
VRCDF
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
VRCDF Max Drawdown
-90.00%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for VRCDF and SPY.
Company Overview
Verici Dx plc
Other OTC
Verici Dx plc, an immuno-diagnostics development company, focuses on the kidney transplantation market. The company develops prognostic and diagnostic tests for kidney transplant patients. Its in-development tests include Clarava, a pre-transplant prognosis test for the risk of early acute rejection; Tuteva, a post-transplant test that focuses on acute cellular rejection; and Protega, a liquid biopsy that aims to predict the risk of fibrosis and long-term graft failure. The company was incorporated in 2020 and is based in Penarth, the United Kingdom.
- Leadership
- Sara jane Barrington
- IPO Date
- May 27, 2022
- Employees
- 19
- Street Address
- Avon House
- Mailing
- Penarth, CF64 2EZ
- Region
- Penarth, GB
- Reporting Currency
- USD
- Investor Line
- +1 615 490 0213
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 6.7
- Price/Book
- 0.6
Growth
- Revenue
- +229.6%
- EPS
- +51.3%
- Free Cash Flow
- +15.9%
Profitability
- Gross Margin
- 105.8%
- Operating Margin
- -472.6%
- Net Margin
- -468.3%
- ROE
- -178.4%
- ROIC
- -243.2%
Balance Sheet
- Debt/Equity
- 0.11
- Current Ratio
- 0.91
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.